Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katharina Buerger

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
Fortschritte Der Neurologie-Psychiatrie|July 20, 2022
Daniela Frimmer, Katharina Buerger
Brain Research Bulletin|August 12, 2003
Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau proteinHarald Hampel, Alexander Goernitz, Katharina Buerger
CNS Neuroscience & Therapeutics|October 21, 2009
Biological marker candidates of Alzheimer's disease in blood, plasma, and serumPhiline Schneider, Harald Hampel, Katharina Buerger
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 22, 2007
Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmasMuamer Omerovic, Harald Hampel, Stefan J Teipel, et al.
International Psychogeriatrics|August 19, 2007
Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementiaStefan Lorenzl, Katharina Buerger, Harald Hampel, et al.
Neurobiology of Aging|December 27, 2016
Cognitive reserve moderates the association between functional network anti-correlations and memory in MCINicolai Franzmeier, Katharina Buerger, Stefan Teipel, et al.
Brain : a Journal of Neurology|July 7, 2007
No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's diseaseKatharina Buerger, Irina Alafuzoff, Michael Ewers, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 30, 2012
Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controlsMarkus J Schwarz, Gilles J Guillemin, Stefan J Teipel, et al.
Neuroscience Letters|March 5, 2003
Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's diseasePeter Schönknecht, Johannes Pantel, Aoife Hunt, et al.
Alzheimer'S Research & Therapy|August 13, 2021
Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individualsDavina Biel, Matthias Brendel, Anna Rubinski, et al.
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
Fortschritte Der Neurologie-Psychiatrie|July 20, 2022
Daniela Frimmer, Katharina Buerger
Brain Research Bulletin|August 12, 2003
Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau proteinHarald Hampel, Alexander Goernitz, Katharina Buerger
CNS Neuroscience & Therapeutics|October 21, 2009
Biological marker candidates of Alzheimer's disease in blood, plasma, and serumPhiline Schneider, Harald Hampel, Katharina Buerger
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 22, 2007
Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmasMuamer Omerovic, Harald Hampel, Stefan J Teipel, et al.
International Psychogeriatrics|August 19, 2007
Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementiaStefan Lorenzl, Katharina Buerger, Harald Hampel, et al.
Neurobiology of Aging|December 27, 2016
Cognitive reserve moderates the association between functional network anti-correlations and memory in MCINicolai Franzmeier, Katharina Buerger, Stefan Teipel, et al.
Brain : a Journal of Neurology|July 7, 2007
No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's diseaseKatharina Buerger, Irina Alafuzoff, Michael Ewers, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 30, 2012
Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controlsMarkus J Schwarz, Gilles J Guillemin, Stefan J Teipel, et al.
Neuroscience Letters|March 5, 2003
Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's diseasePeter Schönknecht, Johannes Pantel, Aoife Hunt, et al.
Alzheimer'S Research & Therapy|August 13, 2021
Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individualsDavina Biel, Matthias Brendel, Anna Rubinski, et al.
Pageof 17